X-Heal Diagnostics winner of the 17th Venture Challenge edition

Today at the Dutch Biotech Event, Chrétien Herben, director LifeSciences@Work Accelerator, announced X-Heal Diagnostics as winning team of the 17th edition of the Venture Challenge. X-Heal Diagnostics has developed the X-halyzer technology, a patented diagnostic technology that allows specific detection of bacteria from exhaled air within one hour, directly enabling targeted treatment for patients with chronic lung diseases.

According to the Venture Challenge Jury the technological innovation of X-Heal Diagnostics addresses the worldwide issues of Antimicrobial Resistance (AMR) by its quick and specific detection. The X-halyzer technology has been developed by researchers from Radboud University Medical Center and Innosieve Diagnostics BV.

"Our ambition is to market our X-halyzer technology for different indications and target groups, such as the diagnosis of lung infections in cystic fibrosis patients and diagnosis of tuberculosis" states Marien de Jonge, Head of the Laboratory of Pediatric Infectious Diseases, Radboudumc.

The Venture Challenge is a bi-annually coaching programme of the valorisation activities of the Top Sector Life Sciences & Health.

Source: Lifesciences@work